Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 1 Interventional

A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity

ClinicalTrials.gov ID: NCT07940582

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07940582. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-human Dose Study Investigating Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC0721-5186 in Female Participants Living With Overweight or Obesity

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being done to look at the safety and how the body takes up, breaks down and removes NNC0721-5186 in people living with overweight or obesity when compared to placebo. In the first 3 dosing groups, NNC0721-5186 will also be compared with semaglutide, a medicine already approved for weight management. Participants will either get NNC0721-5186, semaglutide, or placebo. Which treatment participants get is decided by chance.

Study identification

NCT ID
NCT07940582
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
102 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 13, 2026 (Estimated)
Primary completion
May 29, 2028 (Estimated)
Completion
May 29, 2028 (Estimated)
Last update posted
Nov 17, 2026

2026 – 2028

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
[Legal] Altasciences Clinical Los Angeles, Inc. & Altasciences Professional Los Angeles, P.C. Cypress California 90630 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07940582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.